| Trial ID: | L3579 |
| Source ID: | NCT03842267
|
| Associated Drug: |
Gemigliptin 50mg
|
| Title: |
A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Gemigliptin 50mg|DRUG: Gemigliptin Placebo
|
| Outcome Measures: |
Primary: Changes from baseline HbA1c at week 24, Baseline (week 0) and week 24 |
|
| Sponsor/Collaborators: |
Sponsor: LG Chem
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
315
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2019-05-13
|
| Completion Date: |
2022-11-30
|
| Results First Posted: |
|
| Last Update Posted: |
2023-03-10
|
| Locations: |
LG chem, Seoul, Gangseo-Gu, 07795, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT03842267
|
